chemoprevention colorectal cancer targeting apc-deficient cells apoptosis 
cancer chemoprevention uses natural synthetic biological substances reverse suppress prevent either initial phase carcinogenesis progression neoplastic cells cancer1 holds promise overcoming problems associated treatment late-stage cancers however broad application chemoprevention compromised present limited effectiveness potential toxicity overcome challenges developed new chemoprevention approach specifically targets premalignant tumour cells apoptosis show deficiency adenomatous polyposis coli apc gene subsequent activation beta-catenin lead repression cellular caspase- inhibitor c-flip also known cflar expression activation c-myc all-trans-retinyl acetate rac independently upregulates tumour necrosis factor-related apoptosis-inducing ligand trail death receptors suppresses decoy receptors thus combination trail rac induces apoptosis apc-deficient premalignant cells without affecting normal cells vitro addition show short-term non-continuous trail rac treatment induce apoptosis specifically intestinal polyps strongly inhibit tumour growth prolong survival multiple intestinal neoplasms c57bl/6j-apcmin/j apcmin mice approach demonstrate trail rac induce significant cell death human colon polyps providing potentially selective approach colorectal cancer chemoprevention targeting apc-deficient cells apoptosis 
